ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lamivudine

Also written as “Lamivudine/Zidovudine”, “Lamivudine (3TC)” and “lamivudine”.

Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · Infections · Hepatitis B, led by 5 companies.

Drug pageLamivudine: every studyMany companies study it; this page follows only the 49 they lead. All 239 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 15, 200049 company-led studies, 2 open or runningNext primary completion: Sep 14, 2032 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only352 open or runningphase 4since Feb 15, 2000Nov 2, 1999Sep 14, 2032phase 3 · NCT07393659
Bristol-Myers Squibbits history only70 open or runningphase 4since Jun 27, 2005Nov 2, 1999none ahead
Abbottits history only40 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Dupont Merckits history only20 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
triangle-pharmaceuticals10 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead

Also a collaborator on its studies: PPD Development, LP and Dupont Applied Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of triangle-pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 1999First study: phase 3 study in HIV InfectionsFirst studyNCT00002416 · 390 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

The one study triangle-pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00002416HIV Infections · United States3Completed390

How it is read

Names in the registry

  • “Lamivudine”, 35 entries
  • “Lamivudine/Zidovudine”, 6 entries
  • “Lamivudine (3TC)”, 4 entries
  • “lamivudine”, 3 entries
  • “DTG/3TC”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.